4.7 Article

Urinary pharmacokinetics of betalains following consumption of red beet juice in healthy humans

Journal

PHARMACOLOGICAL RESEARCH
Volume 52, Issue 4, Pages 290-297

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2005.04.005

Keywords

betalains; human; pharmacokinetics; renal excretion; red beet

Ask authors/readers for more resources

The aim of the present pilot study was to characterise the renal elimination of betalains after consumption of red beet juice (RBJ). Six healthy, non-smoking female volunteers were given a single oral dose of either 500 mL of a commercial RBJ containing 362.7 mg of betalains and 500 mL of tap water, respectively, in a sequential manner. Urine was collected in intervals up to 24 h post-dose. Renal excretion of betalains was determined spectrophotometrically and quantified as betanin-equivalents. In addition, the identity of individual compounds was confirmed by HPLC coupled with diode-array detection and positive ion electrospray mass spectrometry, respectively. The amount (mean +/- S.D.) of intact betalains (betanin and isobetanin) recovered in urine was 1001 +/- 273 mu g corresponding to 0.28 +/- 0.08% of the administered dose. Maximum excretion rates were observed after a median t(max.R) of 3.0 h (range 2.5-8.0 h) amounting to 91.7 +/- 30.1 mu g/h. The terminal elimination rate constant (lambda(z)) and the corresponding half-life were 0.097 +/- 0.021 h(-1) and 7.43 +/- 1.47 h, respectively. Using the lambda(z) estimates obtained the expected total betalain amount excreted in urine was 1228 +/- 291 mu g. Based on the results obtained it is assumed that either the bioavailability of the betalains is low or that renal clearance is a minor route of systemic elimination for these compounds. The urinary excretion rates of unmetabolised betalains were fast and appeared to be monoexponential suggesting a one-compartment model. In order to get a more complete picture of the pharmacokinetics and health-promoting properties of red beet betalains, quantitative data on betalain bioavailability should include measurements of unchanged compounds and their corresponding metabolites in plasma, urine and bile. (c) 2005 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available